Drugs / [89Zr]Zr- BI 770371
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05068102 | Mar 2022 → Jan 2026 overdue | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [89Zr]Zr- BI 770371 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05068102 ↗ |